Alpha Tau Medical Ltd.(DRTS)Earnings, Financials & Key Ratios
DRTS•NASDAQ
Price updated Jun 19, 2026
AboutAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Show more
- Revenue$0
- EBITDA-$41M-17.5%
- Net Income-$43M-34.3%
- EPS (Diluted)-0.53-17.8%
- ROE-61%-41.3%
DRTS Key Insights
Alpha Tau Medical Ltd. (DRTS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Profits declining 36.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 15.2% in last year
- ✗Expensive at 10.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DRTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DRTS Price & Volume
Alpha Tau Medical Ltd. (DRTS) stock price & volume — 10-year historical chart
Loading chart...
DRTS Growth Metrics
Alpha Tau Medical Ltd. (DRTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.44%
Return on Capital
10 Years-25.5%
5 Years-25.83%
3 Years-18.74%
Last Year-48.72%
DRTS Recent Earnings
Alpha Tau Medical Ltd. (DRTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.26-100.0%
$0.13
Rev
—
$49,750
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
—
$63,000
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.14-16.7%
$0.12
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.13-8.3%
$0.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.26vs $0.13-100.0% | —vs $49,750 |
| Q2 2026 | Mar 9, 2026 | $0.14vs $0.13-7.7% | —vs $63,000 |
| Q4 2025 | Nov 20, 2025 | $0.14vs $0.12-16.7% | — |
| Q3 2025 | Aug 11, 2025 | $0.13vs $0.12-8.3% | — |
Based on last 12 quarters of dataView full earnings history →
DRTS Peer Comparison
Alpha Tau Medical Ltd. (DRTS) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 IART | 1.37B | 17.58 | -2.61 | 1.53% | -30.15% | -47.65% | 1.95 | |
 ARAY | 41.39M | 0.35 | -22.45 | 2.68% | -10.76% | -77.48% | 2.17 | |
 MRKR | 14.36M | 1.33 | -1.68 | -100% | -5.2% | -0% | ||
 RLAY | 3B | 15.88 | -9.86 | 53.44% | -25.54% | -43.94% | 0.06 | |
 BLCO | 5.3B | 14.87 | -14.58 | 6.47% | -4.21% | -3.37% | 0.82 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 |
Compare DRTS vs Peers
Alpha Tau Medical Ltd. (DRTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DRTS Income Statement
Alpha Tau Medical Ltd. (DRTS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 86K | 776K | 979K | 1.07M | 1.1M | 1.23M |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | -86K▲ 0% | -776K▼ 802.3% | -979K▼ 26.2% | -1.07M▼ 9.7% | -1.1M▼ 2.6% | -1.23M▼ 11.8% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | -802.33% | -26.16% | -9.7% | -2.61% | -11.8% |
Operating Expenses | 8.01M | 9.24M | 13.79M | 32.14M | 34.61M | 34.94M | 41.06M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 1.37M | 1.7M | 2.34M | 11.25M | 9.26M | 7.92M | 10.22M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 6.64M | 7.54M | 11.45M | 20.89M | 26.42M | 27.02M | 30.83M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -1.07M | 0 | 0 |
Operating Income | -8.01M▲ 0% | -9.24M▼ 15.4% | -13.79M▼ 49.2% | -32.14M▼ 133.0% | 35.68M▲ 211.0% | -36.04M▼ 201.0% | -42.29M▼ 17.3% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -15.41% | -49.18% | -133.04% | 211.03% | -201.01% | -17.33% |
EBITDA | -7.94M | -9.16M | -13.01M | -31.16M | 36.75M | -34.94M | -41.06M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | -15.28% | -42.11% | -139.41% | 217.96% | -195.06% | -17.5% |
D&A (Non-Cash Add-back) | 66K | 86K | 776K | 979K | 1.07M | 1.1M | 1.23M |
EBIT | -8.01M | -9.24M | -13.99M | -33.72M | -29.1M | -31.4M | -42.29M |
Net Interest Income | 776K | 396K | -13.06M | 21K | 4.72M | 3.93M | 3.42M |
Interest Income | 776K | 613K | 211K | 1.79M | 4.75M | 4.28M | 3.84M |
Interest Expense | 0 | 217K | 13.27M | 1.77M | 39K | 344K | 419K |
Other Income/Expense | -308K | 520K | -13.47M | -1.61M | 6.54M | 4.3M | -218K |
Pretax Income | -8.32M▲ 0% | -8.72M▼ 4.9% | -27.26M▼ 212.5% | -33.74M▼ 23.8% | -29.14M▲ 13.6% | -31.74M▼ 8.9% | -42.51M▼ 33.9% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 146K | 158K | 7K | 20K | 16K | 6K | 121K |
Effective Tax Rate % | -1.76% | -1.81% | -0.03% | -0.06% | -0.05% | -0.02% | -0.28% |
Net Income | -8.46M▲ 0% | -8.88M▼ 4.9% | -27.27M▼ 207.0% | -33.76M▼ 23.8% | -29.16M▲ 13.6% | -31.75M▼ 8.9% | -42.63M▼ 34.3% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -4.94% | -207.04% | -23.8% | 13.64% | -8.89% | -34.26% |
Net Income (Continuing) | -8.46M | -8.88M | -27.27M | -33.76M | -29.16M | -31.75M | -42.63M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.13▲ 0% | -0.22▼ 69.2% | -0.67▼ 204.5% | -0.53▲ 20.9% | -0.42▲ 20.8% | -0.45▼ 7.1% | -0.53▼ 17.8% |
EPS Growth % | - | -69.23% | -204.55% | 20.9% | 20.75% | -7.14% | -17.78% |
EPS (Basic) | -0.13 | -0.22 | -0.67 | -0.53 | -0.42 | -0.45 | -0.53 |
Diluted Shares Outstanding | 67.62M | 40.43M | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
Basic Shares Outstanding | 67.62M | 40.43M | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
DRTS Balance Sheet
Alpha Tau Medical Ltd. (DRTS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Total Current Assets | 29.83M | 47.45M | 32.64M | 106.48M | 85.76M | 64.23M | 78.3M |
Cash & Short-Term Investments | 28.13M | 46.02M | 31.32M | 104.53M | 81.79M | 59.6M | 76.9M |
Cash Only | 1.83M | 15.6M | 23.24M | 5.84M | 12.66M | 13.72M | 15.98M |
Short-Term Investments | 26.3M | 30.42M | 8.08M | 98.69M | 69.13M | 45.88M | 60.92M |
Accounts Receivable | 141K | 477K | 480K | 32K | 19K | 332K | 36K |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 1.13M | 0 | -8.17M | 0 | -19K | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | -187.3K | 576K | 8.79M | 1.13M | 3.5M | 3.25M | 0 |
Total Non-Current Assets | 1.73M | 5.53M | 9.57M | 13.67M | 21.63M | 21.98M | 28.28M |
Property, Plant & Equipment | 1.71M | 5.39M | 7.55M | 13.28M | 21.16M | 21.54M | 26.88M |
Fixed Asset Turnover | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 16K | 139K | 2.03M | 391K | 471K | 432K | 479K |
Total Assets | 31.56M▲ 0% | 52.99M▲ 67.9% | 42.22M▼ 20.3% | 120.15M▲ 184.6% | 107.39M▼ 10.6% | 86.2M▼ 19.7% | 106.58M▲ 23.6% |
Asset Turnover | - | - | - | - | - | - | - |
Asset Growth % | - | 67.92% | -20.33% | 184.61% | -10.62% | -19.73% | 23.64% |
Total Current Liabilities | 1.35M | 2.09M | 4.41M | 4.34M | 7.1M | 8.68M | 10.51M |
Accounts Payable | 893K | 964K | 1.2M | 1.42M | 2.57M | 3.53M | 3.87M |
Days Payables Outstanding | - | 4.09K | 565.84 | 530.54 | 872.06 | 1.17K | 1.15K |
Short-Term Debt | 0 | 0 | 0 | 0 | 1.06M | 1.01M | 1.13M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 599K | 2.41M | 1.34M | -983K | 389K | 3.78M |
Current Ratio | 22.11x | 22.73x | 7.41x | 24.55x | 12.07x | 7.40x | 7.45x |
Quick Ratio | 21.27x | 22.73x | 9.26x | 24.55x | 12.08x | 7.40x | 7.45x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 30.4M | 59.33M | 72.59M | 10.15M | 15.81M | 14.86M | 18.97M |
Long-Term Debt | 0 | 53.96M | 53.96M | 0 | 5.61M | 5.56M | 6.35M |
Capital Lease Obligations | 0 | 0 | 0 | 4.52M | 6.6M | 5.96M | 6.24M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M |
Other Non-Current Liabilities | 30.4M | 5.37M | 18.62M | 5.63M | 3.6M | 3.34M | 5.35M |
Total Liabilities | 31.75M | 61.42M | 76.99M | 14.49M | 22.91M | 23.54M | 29.48M |
Total Debt | 0 | 53.96M | 53.96M | 5.19M | 13.28M | 12.54M | 13.73M |
Net Debt | -1.83M | 38.37M | 30.73M | -643K | 619K | -1.19M | -2.25M |
Debt / Equity | - | - | - | 0.05x | 0.16x | 0.20x | 0.18x |
Debt / EBITDA | - | - | - | - | 0.36x | - | - |
Net Debt / EBITDA | - | - | - | - | 0.02x | - | - |
Interest Coverage | - | -42.60x | -1.05x | -19.06x | -746.21x | -91.28x | -100.93x |
Total Equity | -193K▲ 0% | -8.43M▼ 4267.4% | -34.78M▼ 312.6% | 105.66M▲ 403.8% | 84.47M▼ 20.0% | 62.67M▼ 25.8% | 77.1M▲ 23.0% |
Equity Growth % | - | -4267.36% | -312.59% | 403.81% | -20.05% | -25.82% | 23.03% |
Book Value per Share | -0.00 | -0.21 | -0.86 | 1.66 | 1.22 | 0.90 | 0.96 |
Total Shareholders' Equity | -193K | -8.43M | -34.78M | 105.66M | 84.47M | 62.67M | 77.1M |
Common Stock | 0 | 690 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -16.69M | -25.57M | -52.84M | -86.6M | -115.76M | -147.51M | -190.14M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -21K | -60.02K | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRTS Cash Flow Statement
Alpha Tau Medical Ltd. (DRTS) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Cash from Operations | -6.91M | -7.25M | -11.81M | -23.88M | -17.96M | -19.78M | -26.68M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -4.93% | -62.9% | -102.16% | 24.8% | -10.16% | -34.87% |
Net Income | -8.46M | -8.88M | -27.27M | -33.76M | -29.16M | -31.75M | -42.63M |
Depreciation & Amortization | 66K | 86K | 776K | 979K | 1.07M | 1.1M | 1.23M |
Stock-Based Compensation | 546K | 596K | 812K | 6.75M | 7.93M | 9.92M | 0 |
Deferred Taxes | 994K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 12K | 50K | 13.29M | 2.46M | -293K | -219K | 12.42M |
Working Capital Changes | -64K | 899K | 585K | -307K | 2.49M | 1.17M | 2.29M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 148K | 114K | 239K | 220K | 1.14M | 965K | 337K |
Cash from Investing | -10.16M | -7.82M | 19.27M | -89.94M | 18.68M | 20.77M | -20.59M |
Capital Expenditures | -1.29M | -3.77M | -2.93M | -904K | -6.4M | -2.24M | -6.08M |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 8.87K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | -8.87K | -4.05M | 22.2M | -89.03M | 25.08M | -103K | 0 |
Cash from Financing | 5.32M | 29.32M | 111K | 96.91M | 5.3M | 25K | 45.77M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 5.25M | 29.32M | 111K | 3.36M | 49K | 25K | 45.77M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 73K | 0 | 0 | 93.54M | 5.25M | 0 | 0 |
Net Change in Cash | -11.77M▲ 0% | 16.17M▲ 237.4% | 7.68M▼ 52.5% | -17.17M▼ 323.5% | 9.12M▲ 153.1% | 1.17M▼ 87.2% | -1M▼ 185.5% |
Free Cash Flow | -8.2M▲ 0% | -11.02M▼ 34.3% | -14.74M▼ 33.8% | -24.78M▼ 68.1% | -24.36M▲ 1.7% | -22.02M▲ 9.6% | -32.76M▼ 48.7% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -34.32% | -33.77% | -68.15% | 1.71% | 9.6% | -48.75% |
FCF per Share | -0.12 | -0.27 | -0.36 | -0.39 | -0.35 | -0.31 | -0.41 |
FCF Conversion (FCF/Net Income) | 0.82x | 0.82x | 0.43x | 0.71x | 0.62x | 0.62x | 0.63x |
Interest Paid | 0 | 0 | 0 | 0 | 52K | 321K | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRTS Key Ratios
Alpha Tau Medical Ltd. (DRTS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -95.27% | -30.67% | -43.16% | -61% |
Return on Invested Capital (ROIC) | - | -49.68% | -79.9% | -47.74% | 28.15% | -36.88% | -46.53% |
Debt / Equity | - | - | - | 0.05x | 0.16x | 0.20x | 0.18x |
Interest Coverage | - | -42.60x | -1.05x | -19.06x | -746.21x | -91.28x | -100.93x |
FCF Conversion | 0.82x | 0.82x | 0.43x | 0.71x | 0.62x | 0.62x | 0.63x |
Related:DRTS Dividend History·DRTS Revenue History·DRTS Price History·DRTS P/E History·DRTS Financial Ratios·DRTS Institutional Holders
DRTS Frequently Asked Questions
Alpha Tau Medical Ltd. (DRTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alpha Tau Medical Ltd. (DRTS) grew revenue by 0.0% over the past year. Growth has been modest.
Alpha Tau Medical Ltd. (DRTS) reported a net loss of $42.6M for fiscal year 2025.
Dividend & Returns
Alpha Tau Medical Ltd. (DRTS) has a return on equity (ROE) of -61.0%. Negative ROE indicates the company is unprofitable.
Alpha Tau Medical Ltd. (DRTS) had negative free cash flow of $32.8M in fiscal year 2025, likely due to heavy capital investments.